P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2018

January 2018 | 34 pages | ID: PE183F8E692EN
Global Markets Direct

Abstracts

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2018

SUMMARY

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated ion channel. It is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules.

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Gastrointestinal and Genetic Disorders which include indications Inflammation, Alzheimer's Disease, Basal Cell Carcinoma (Basal Cell Epithelioma), Bipolar Disorder (Manic Depression), Charcot-Marie-Tooth Disease Type I A, Epilepsy, Inflammatory Bowel Disease, Major Depressive Disorder, Multiple Sclerosis, Neuropathic Pain and Solid Tumor.

The latest report P2X Purinoceptor 7 - Pipeline Review, H1 2018, outlays comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
• The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects
• The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development
Affectis Pharmaceuticals AG
Axxam SpA
Biosceptre International Ltd
Evotec AG
Johnson & Johnson
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles
AFC-5128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-010t - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-06v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVT-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5446 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Products
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Product Development Milestones
Featured News & Press Releases
Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma
Dec 18, 2014: Alzheimer’s Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer’s Disease
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists
Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT
Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Affectis Pharmaceuticals AG, H1 2018
Pipeline by Axxam SpA, H1 2018
Pipeline by Biosceptre International Ltd, H1 2018
Pipeline by Evotec AG, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Affectis Pharmaceuticals AG
Axxam SpA
Biosceptre International Ltd
Evotec AG
Johnson & Johnson